Covid-19: vaccination targeting Omicron begins, what you need to know – Yahoo France

Covid-19: vaccination targeting Omicron begins, what you need to know – Yahoo France

New vaccines designed to protect against severe forms of the Omicron variant sublines are available from this Monday 3 October for frail people, over 60 years or carers.

COVID – Next Generation Messenger RNA vaccines, he says “bivalent”, are now available in pharmacies and vaccination centers, while contamination and hospitalization figures have been increasing on average in France since mid-September. These vaccines have been approved High Office of Health (HAS) on September 20 after the approval of chEuropean Medicines Agency (EMA) a few days earlier.

However, this date of Monday 3 October is two weeks earlier than the timetable recommended by HAS, which in its opinion recommended “link this new campaign with the seasonal flu vaccination that starts on October 18”, commemorating it “Simultaneous injection of two vaccines is possible if it is done at two different injection sites. »

Are you eligible?

These new vaccines are offered and recommended for:

– People aged at least 60 years
– residents of nursing homes and long-term care units (USLD)
– Immunocompromised people
– Adults aged at least 18 years at risk of severe form (with comorbidities, pregnant women)
– People living in the company of another person belonging to one of the above categories
– Caregivers and other professionals in the health and medical-social sector

If you are on this list, the deadlines for becoming eligible from the last vaccination vary: vaccination is possible for people aged 80 and over, residents of nursing homes and people with weakened immune systems if they had their last vaccination there. Others have to wait six months if they have not tested positive for Covid in the last 3 months.

Are these vaccines more effective?

According to a communicated of Moderna published on June 8, 2022, the results of this new bivalent vaccine are promising. The tests were carried out on 437 people, half of the people received the vaccine against the original virus as a booster and the other half were given this new bivalent vaccine.

One month after the injection, people vaccinated with the new strain show antibodies 8 times higher than others. According to the lab, the vaccine “shows (…) also higher response against Omicron BA.4/5 sub-lines” compared to the first-generation vaccine. However, these results still need to be consolidated.

As for their ability to reduce the very strong infectivity of this variant, “Nothing is certain at this point, but they could reduce the risk of transmission by 40 to 50%, which hasn’t happened before.” he explained a few days ago HuffPost, Bruno Lina, virologist reappointed to the new scientific committee. Professor Antoine Flahaut, director of the Institute of Global Health at the University of Geneva, said he was cautious about “superiority” of these vaccines compared to the first formulations.

Are both vaccines available yet?

In the first few days, only the 576,000 doses of Moderna’s Spikevax vaccine that have already been received will be available in France. Pfizer/BioNTech vaccines adapted to BA.5 will have to wait a few more days, most in cases sequenced since June 2022. “No supply voltage” is expected by health authorities as this recall is entirely voluntary and is currently only accessible to a certain audience.

These two vaccines can be used “indifferently”indicates HAS, although the Moderna vaccine is not recommended for those under 30 for one year due to greater cardiac risks.

A successful campaign can break the eighth wave, currently observed in Western Europe. The increase in detected cases is beginning to be reflected in the number of resuscitations recorded in France, as you can see in the graphs below.

Read more

VIDEO – Concerns after the discovery of a new virus close to Covid-19 in Russia

Read also


These sick days will soon no longer be paid


Ministry of Health announced that 4,300 hospital beds will be lost in 2021


Author Image

Leave a Reply

Your email address will not be published. Required fields are marked *